Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Highlights in urothelial cancer for ASCO GU 2021

Shilpa Gupta • 17 Feb 2021
GU Cancers 2021
Bladder Cancer Genitourinary Cancer Antibodies Nivolumab
CheckMate 274

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, shares her highlights in urothelial cancer from the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2021. Dr Gupta discusses the endpoints, results, and importance of the Phase III CheckMate 274 trial (NCT02632409). The key finding of this trial was that nivolumab improved disease-free survival in the overall population as well as the PD-L1 high population of patients, but further studies are needed to determine overall survival rates with nivolumab. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Shilpa Gupta

The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer
1:11
The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer
Shilpa Gupta • 3 Jun 2023
The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape
1:02
The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape
Shilpa Gupta • 3 Jun 2023
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
6:02
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
Shilpa Gupta • 3 Jun 2023
MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer
2:06
MAIN-CAV: maintenance cabozantinib and avelumab in urothelial cancer
Shilpa Gupta • 3 Jun 2023

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals